Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Retained Earnings (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Retained Earnings for 13 consecutive years, with -$164.5 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 9.56% to -$164.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$164.5 million through Dec 2025, up 9.56% year-over-year, with the annual reading at -$164.5 million for FY2025, 9.56% up from the prior year.
  • Retained Earnings for Q4 2025 was -$164.5 million at Niagen Bioscience, up from -$168.7 million in the prior quarter.
  • The five-year high for Retained Earnings was -$154.8 million in Q2 2021, with the low at -$191.0 million in Q2 2024.
  • Average Retained Earnings over 5 years is -$179.5 million, with a median of -$183.1 million recorded in 2022.
  • The sharpest move saw Retained Earnings decreased 19.13% in 2021, then increased 10.8% in 2025.
  • Over 5 years, Retained Earnings stood at -$169.0 million in 2021, then dropped by 9.79% to -$185.5 million in 2022, then decreased by 2.68% to -$190.5 million in 2023, then grew by 4.49% to -$181.9 million in 2024, then rose by 9.56% to -$164.5 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$164.5 million, -$168.7 million, and -$173.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.